CTMG attends FDLI premier Annual Conference 2015


CTMG’s CEO, Anton-Lewis Usala, MD returned to Washington DC this week to present at the Food and Drug Law Institute’s premier Annual Conference, focused this year on Recent Trends in Data Integrity Compliance and Enforcement. Dr. Usala profiled the key strengths of the SSRO approach – Adaptive Investigative-Site Management (AIM) – in ensuring that high […]

CTMG President and CEO speaks at FDLI Conference


CTMG President and CEO, Anton-Lewis Usala, MD , was invited to speak at the Food and Drug Law Institute’s Enforcement, Litigation & Compliance Conference on December 9, 2014 in Washington, DC. Dr. Usala spoke on issues affecting “Clinical Trial Data Integrity—The Investigative Site”. The FDLI Enforcement, Litigation & Compliance Conference is held to examine the […]

Faster Enrollment. Better Data. Period™

After hearing from our Sponsor and Physician partners, CTMG is changing the way we convey what makes us different — our unique business structure, superior processes, and cGMP-based approach – all of which assure you Faster Enrollment. Better Data. Period™.   We’ll debut a new website soon, featuring a new logo and messaging, and invite you to […]

What is CTMG’s new “SSRO” terminology all about?


CTMG will celebrate its tenth anniversary as the world’s first Site Specific CRO (‘SS-CRO’). This unique entity has provided unparalleled speed and certainty to Investigative Site clinical trial completion timelines. As described in the Food and Drug Law Institute’s Food and Drug Policy Forum (http://www.fdli.org/resources/resources-order-box-detail-view/can-fda-accelerate-clinical-trial-timelines-and-completion-using-documented-cgmp-processes-), the SS-CRO model provides design-reviewed processes that translate a Sponsor’s […]

CTMG President and CEO published in the Food and Drug Policy Forum

The document above was posted with permission of the Food and Drug Law Institute. This document can be viewed here.